Skip to content
Clinical Trials – home

Medicinski Centar Hipokrat-N EOOD

Verified siteinfo

Bulgaria Ulitsa Dragota 6, 4003 Plovdiv, Bulgaria

  • 4 trials recruiting
  • Chronic kidney disease · Arteriosclerosis · Atrial fibrillation
  • Adults and children

About Specializations

Medicinski Centar Hipokrat-N EOOD in Plovdiv, Bulgaria specialises in clinical trials of conditions such as Chronic kidney disease, Arteriosclerosis, Atrial fibrillation, Cerebrovascular accident prophylaxis, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

At Medicinski Centar Hipokrat-N EOOD in Plovdiv, clinical research in cardiovascular diseases focuses on reducing major heart and stroke risks in people with established vascular disease and irregular heart rhythm. These studies are exploring new ways to improve prevention, lower complications, and better protect patients at high risk.

  • Prevention of stroke and systemic embolism in atrial fibrillation
  • Lowering the risk of major cardiovascular events in atherosclerotic cardiovascular disease
  • Evaluating therapies aimed at improving outcomes in established cardiovascular disease

Overall, this area is centered on testing new treatment options and measuring whether they can offer stronger protection than existing approaches.

Metabolism and Kidney Disease

The site is also active in metabolism-related research, especially studies linking kidney health with blood pressure control and protein loss in the urine. These trials are designed to slow the progression of chronic kidney disease and improve long-term kidney function for people living with advanced renal conditions.

  • Slowing progression in chronic kidney disease with high blood pressure
  • Reducing albuminuria and high proteinuria in kidney disease
  • Testing treatments that may better preserve kidney function over time

Research in this field is aimed at improving disease control and finding more effective ways to delay kidney decline.

Bacterial Infections and Mycoses

Another important area of research at this hospital/clinic involves bacterial infections and mycoses, with a focus on preventing recurrence of Clostridioides difficile infection. The studies are intended to improve infection control and reduce the chance that this difficult-to-treat condition returns after treatment.

  • Preventing recurrent Clostridioides difficile infection
  • Assessing new approaches to reduce infection relapse
  • Supporting better outcomes for patients with recurring intestinal infection

This line of research is centered on testing whether newer therapies can provide more reliable protection against repeat infection.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ulitsa Dragota 64003 PlovdivBulgaria
Recruiting now
4 trials
Conditions studied
9
Partner status
Verified site

More sites in PlovdivBulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

13 clinical trials

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

NHS7108 for Exocrine Pancreatic Insufficiency in Adult Patients

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Amylase

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bacilli, Cluster Xvii, Strain Relative Clostridium_Aq Innocuum, Live
  • Sponsor:Vedanta Biosciences Inc.

Chronic kidney disease

Not yet recruiting

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Arteriosclerosis

Not recruiting

Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Study on the Effects of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease and High Protein Levels

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:AstraZeneca AB

Chronic kidney disease+1

Not recruiting

Study on Baxdrostat and Dapagliflozin for Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

Study on Balcinrenone and Dapagliflozin for Adults with Chronic Kidney Disease and Albuminuria

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.